logo
Liverpool Transfer News: £50m forward 'option' eyeing Premier League move

Liverpool Transfer News: £50m forward 'option' eyeing Premier League move

Yahoo14 hours ago
It's currently looking incredibly likely that Liverpool do not bring in any other forwards, despite needed two new recruits in order to properly to address their lack of depth in the attacking areas.
Alexander Isak is the only real name that remains on our radar, but his situation is more complicated than ever before, with Newcastle requiring two strikers to replace him, while no one looks likely to join. Few clubs are willing to let any of their players go as the transfer window closes in two weeks.
🔴 Shop the LFC 2025/26 adidas home range
🚨2025/26 LFC x adidas range🚨
LFC x adidas
Shop the home range today!
LFC x adidas
Shop the goalkeeper range today
LFC x adidas
Shop the new adidas range today!
Previously, it was considered that the Reds could look at bringing in a high-quality winger instead of Isak if it became apparent that securing a deal for the Swede was not possible this summer, but rumours with targets have now stopped and the chances of a high-value move are now pretty slim.
🔴 Shop the LFC 2025/26 adidas away range
But we know that the club has the budget to make a move on someone and Richard Hughes and FSG love a market opportunity to take advantage of. For £50m, the Reds might have a solution in mind.
Lookman has his bags packed ready for a move
The Atalanta winger Ademola Lookman has been available all summer and for a long time it has looked inevitable that he would be staying in Italy this season, hoping to move to Inter Milan.
However, the negotiations that had been taking place have since collapsed with the two clubs disagreeing on the transfer fee. Inter had offered €45m which is around €5-15m less than what Atalanta had been hoping for - the reports on his asking price vary between €50m-60m.
As such, the deal is 'over' according to Fabrizio Romano, with fresh talks still possible but unlikely at this stage, although Lookman is confident that he will leave Atalanta and play elsewhere this season.
In his latest video on YouTube, he added: "Premier League clubs are aware of the situation and the CEO of Atalanta - Antonio Percassi - was in England in the last few weeks to negotiate for Rodrigo Muniz, but also for the situation of Ademola Lookman to try and find different clubs for Lookman because they were not able to negotiate an agreement with Inter for the striker."
As such, it's entirely plausible that Liverpool could have been one of those clubs and Lookman's record as a striker, a left-winger, a right-winger and a second striker makes him an ideal option.
He could cover Mohamed Salah at times, which offering help to Cody Gakpo and it's also plausible that he could play in conjuncture with Hugo Ekitike. Players like him don't come around very often.
Of course, Isak might still be heavily on the radar for a January move if this summer isn't his time, but the lack of squad depth could in part be solves by Lookman's arrival, solidifying our forward options.
At worst it appears as though £50m would be required to get the 27-year-old over the line and the obvious downside is that he is likely to miss part of the season through playing in the African Cup of Nations, as well Salah, but the player has proven he can be a really valuable asset to any team.
Other teams that might consider a move for him include Arsenal, since their left-wing problem remain a concern, but Liverpool are one of the few clubs with the cheque already written to get the job done.
Beside the age profile, there really aren't many better options available to address our specific needs.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Villarreal agree personal terms with Chelsea star
Villarreal agree personal terms with Chelsea star

Yahoo

time21 minutes ago

  • Yahoo

Villarreal agree personal terms with Chelsea star

La Liga outfit Villarreal have reached an agreement on the personal terms of a contract with a member of the defensive ranks at Premier League giants Chelsea. That's according to transfer insider Fabrizio Romano, who points towards Renato Veiga as the player in question. Defender Veiga is for his part expected to be on the move before the summer transfer window is out. This comes with the Portuguese, fresh off a solid loan stint with Juventus over the 2nd half of last season, not featuring in the plans of Chelsea boss Enzo Maresca. Held in high regard across the continent, a number of bids, in turn, are understood to have been tabled for Veiga of late. And as alluded to above, this week, one of the 22-year-old's many suitors have found an agreement with the player himself. As per a report from journalist Fabrizio Romano: 'Villarreal have agreed personal terms with Renato Veiga! Talks are well underway with Chelsea. The Spanish club is negotiating to agree on terms also with Chelsea. Current proposal: €24m plus add-ons, trying to get closer to €30m package.' Conor Laird – GSFN

Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow
Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow

Yahoo

time21 minutes ago

  • Yahoo

Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow

Serie A giants Milan can close their move for Bayer Leverkusen striker Victor Boniface as early as tomorrow. The Rossoneri made a move for the player earlier today, after having been linked with a host of strikers in the last two weeks. MilanNews report that work is ongoing at Milan to close a deal for Boniface quickly and talks have now advanced quickly with Bayer Leverkusen. Some steps are remaining to finalise the deal and Milan are very confident of signing the player and the move can close as early as tomorrow. Max Allegri's side will sign the Nigerian for an initial loan deal with an option to buy for €30 million. Manchester United's Rasmus Hojlund was initially believed to be a key target but Napoli are making progress for the Dane now, even if Milan had been coming close to signing him over the last week or so. Kaustubh Pandey I GIFN

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Yahoo

time21 minutes ago

  • Yahoo

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,115,191 shares (each share carrying one vote), corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification forms. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam Lange (Investors) Vice President, Investor Relations alange@ Neshat Ahmadi (Investors) Investor Relations Manager neahmadi@ Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications akrassowska@ Attachments 20250819 FSA - Standardformular english Van Herk Investments BV_signed 20250819 FSA - Standardformular english Van Herk Management Services BV_signedError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store